Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
Status:
Terminated
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by
blocking the enzymes necessary for tumor cell growth.
PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have
relapsed prostate cancer following radiation therapy or radical prostatectomy.